Bonus Group, a company traded in Tel Aviv, has jumped by 7.75% and completed a jump of more than 170% in the last month.
The jump in the stock yesterday was recorded after the Ministry of Health approved to the company progress in testing the corona drug on humans.
The company presented positive data and was able to cure severe patients in Corona as part of a clinical trial conducted at Rambam Hospital. Life-threatening.
Phase II of the clinical trial for the treatment of respiratory distress will include up to 50 corona patients in critical condition, who are in life-threatening respiratory distress, and will test the efficacy and safety of treatment using the cellular drug MesenCure, compared to a control group.
The experimental group will receive three doses of the drug intravenously.
Dr. Maretzky,
Dr. Shai Maretzky, CEO of Bonus Biogroup, told Israel Today that "in fact we have published 'very impressive results according to which the overwhelming majority of corona patients in a difficult and life-threatening condition, who were treated at Rambam Medical Center using the drug MesenCure, recovered within Shortly after treatment and released to their home.
They were released on the last day of treatment until the next day.
That means it is a very short term.
Corona patients in a critical condition suffer from a process in which the immune system becomes overactive and then the patient’s lungs are flooded with cells of the immune system, causing severe and life-threatening respiratory distress.
"We showed that the condition of all but one of the patients who were ill, including those with background illnesses, improved in a short time, including an improvement in stature and a decrease in inflammation indices. We reported about 20 patients but every day there are more patients, and we will report again when the trial ends." .
Maretzky explained the importance of the drug and claimed that "today there is no drug to treat corona patients. There is relief and help with respiratory support. Here we are talking about a drug that can treat new corona patients, take them out of hospitals and relieve the load from the medical system." "In hospitals. The drug is suitable for a healthy donor. It is important to say that from one donor we know how to treat 50,000 patients. Therefore, we have the ability to treat many populations in a wide variety of countries."
When is it expected to be happy?
"We are currently in a clinical trial and we will do it as fast as we know. During this period, for example, there are 500 difficult patients and this brings a solution to recruitment for the trial. It is not that there is a shortage of patients. In the country.
That way we can help more patients in the hospitals.
"The corona virus, as we all know and know, is not going anywhere. It will continue to accompany us in the coming years by more violent and less violent variants. We need to live with the corona. The ability to function and not bring hospitals into a state of collapse depends on the ability to treat patients well. Who are in a difficult situation in the hospitals. "
How much will the medicine cost?
"As much as it does not cost, it will certainly cost much less than hospitalizations of corona patients in critical condition."